Nexell Therapeutics Inc.
- Share via
The Irvine biotechnology company said it lost $7.1 million, or 37 cents a share, for the third quarter, compared with a net loss of $13 million, or 71 cents a share, a year ago. Revenue more than doubled to $4.5 million from $2.2 million.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
